Currently, there is no consensus in the management of anti-TNF failures in BD, and alemtuzumab is suggested in UK treatment pathways for refractory cases (http://www.behcets.nhs.uk/download/behcets-drug-pathway/). The gene discussed is TNF; the disease is Behcet disease.